Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.
The brokerage highlighted limited adoption of high-dose Eylea amid rising branded and biosimilar competition. UBS projects a 14% drop in Eylea revenue for 2025, with further declines in 2026.
“We believe there is a disconnect between the market's shorter-term focus on Eylea revenues vs. REGN's focus on building a long-term sustainable business,” analyst said.
“Eylea high dose adoptions are still limited at this stage, and with the backdrop of branded and biosimilar competition we don’t expect an inflection in the near-term.”
While Regeneron’s pipeline holds promise in obesity and severe food allergies, UBS flagged long development timelines and the need for proof-of-concept data. Near-term upside from these programs remains limited.
UBS noted that the stock’s valuation, trading at 15x earnings, reflects its innovation but sees investors pivoting to peers with stronger short-term growth.
Regeneron shares are trading near pre-Eylea HD approval levels, which UBS considers fair value. The volatile macro environment adds to downside risks, the note cautioned.